Abstract:ID 92155 Poster Board 478 The Glucagon-like peptide 1 receptor (GLP-1R) belongs to the Class B G-protein coupled receptors (GPCRs) and is a well-established target for treating type 2 diabetes. Recent clinical-trial data suggest that GLP-1R agonistic drugs not only significantly reduce body weight in individuals with obesity, but may also offer protection against serious heart disease and drug/alcohol addiction related issues. Consequently, GLP-1R has become one of the most intriguing and extensively studied Class B GPCRs. Although GLP-1R agonist-based therapies, including various GLP-1 analog drugs, are highly successful and available in the market, most are peptidic in nature and require intravenous ( iv ) mode of administration. Thus, it remains a challenge to develop nonpeptidic agonist drugs targeting GLP-1R. A promising approach, involves the development of small molecule positive allosteric modulators (PAMs) of GLP-1R, which have a greater potential for more convenient oral ( po ) administration. Building upon our prior work that identified two 2-aminothiophene-based small-molecule PAMs of GLP-1R, we conducted a series of structural SAR optimizations, as well as in vitro and in vivo studies. This effort led to the identification of 2-aminothiophene derivative, I-187 (MW 299), which exhibited an approximately 2-fold increase in insulin secretion at 5 μM when combined with the GLP-1 peptide at 10 nM. I n vivo studies using CD1 mice revealed a 50% reduction in glucose levels after 60 minutes at a dose of 10 mg/kg b.w. More notably, co-treatment with sitagliptin, an inhibitor of the GLP-1 degrading enzyme dipeptidyl peptidase IV, demonstrated that I-187 synergistically lowered blood glucose levels by approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. These promising results, coupled with the favorable drug-like properties of the compound, suggest that I-187 is a compelling lead compound for future drug development. Furthermore, this approach can potentially be applied to the development of allosteric modulation of other GPCRs. This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R15GM140406.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

Discovery of Cyclic Guanidines As Potent, Orally Active, Human Glucagon Receptor Antagonists

Discovery and Investigation of A Novel Class of Thiophene-Derived Antagonists of the Human Glucagon Receptor

A Novel Series of Indazole-/Indole-based Glucagon Receptor Antagonists

Discovery of potent, orally active benzimidazole glucagon receptor antagonists

Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1h-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes.

Anti-diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist.

A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Hepatic Glucagon Receptor Binding and Glucose-Lowering in Vivo by Peptidyl and Non-Peptidyl Glucagon Receptor Antagonists.

Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1 H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1h-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures

Potential allosteric pockets identification of glucagon receptor based on molecular dynamics simulations

Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs

Discovery and Optimization of N -Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Discovery of Novel and Selective GPR17 Antagonists as Pharmacological Tools for Developing New Therapeutic Strategies in Diabetes and Obesity